{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T09:38:41Z","timestamp":1793093921737,"version":"4.5.0"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004047","name":"Karolinska Institute","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004047","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Brain"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Glaucoma is a neurodegenerative disease affecting retinal ganglion cells (RGCs), with a multifactorial genesis that includes inflammation and vascular dysfunction. Emerging evidence suggests that glucagon-like peptide 1 receptor agonist (GLP-1RAs) may serve as promising neuroprotective agents in glaucoma. In this study, we investigated the neuroprotective potential of the GLP-1RA semaglutide (SEM) in a rat model of ocular hypertension (OHT) induced by paramagnetic bead injections in Brown Norwegian rats. Rats were divided into four cohorts, two normotensive (NT) cohorts, and two OHT cohorts, treated with either SEM or saline (HBSS), which served as control. Systemic SEM or HBSS administration was initiated simultaneously with OHT induction. We observed that SEM administration seemed to delay the increase in intraocular pressure (IOP) associated with OHT. Although SEM administration did not improve RGC survival, it significantly improved astrocytic fractal dimension value and lacunarity. In conclusion, our findings suggest that GLP-1RAs may exert neuroprotective effects by delaying IOP elevation and preventing OHT-induced reactive astrocyte and vascular remodeling. These findings highlight the potential of GLP-1RAs for retinal neuroprotection, but further studies are needed to elucidate their applicability in glaucoma.<\/jats:p>","DOI":"10.1186\/s13041-025-01224-8","type":"journal-article","created":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T09:15:00Z","timestamp":1751361300000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Systemic semaglutide provides a mild vasoprotective and antineuroinflammatory effect in a rat model of ocular hypertensive glaucoma"],"prefix":"10.1186","volume":"18","author":[{"given":"Zaynab A.","family":"Mouhammad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Rombaut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariana Yolotzin Garc\u00eda","family":"Berm\u00fadez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rupali","family":"Vohra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James R.","family":"Tribble","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pete A.","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam","family":"Kolko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,1]]},"reference":[{"key":"1224_CR1","doi-asserted-by":"publisher","first-page":"824054","DOI":"10.3389\/fnins.2022.824054","volume":"16","author":"ZA Mouhammad","year":"2022","unstructured":"Mouhammad ZA, Vohra R, Horwitz A, Thein AS, Rovelt J, Cvenkel B, et al. Glucagon-Like peptide 1 receptor Agonists - Potential game changers in the treatment of glaucoma?? Front Neurosci. 2022;16:824054.","journal-title":"Front Neurosci"},{"issue":"11","key":"1224_CR2","doi-asserted-by":"publisher","first-page":"2081","DOI":"10.1016\/j.ophtha.2014.05.013","volume":"121","author":"YC Tham","year":"2014","unstructured":"Tham YC, Li X, Wong TY, Quigley HA, Aung T, Cheng CY. Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis. Ophthalmology. 2014;121(11):2081\u201390.","journal-title":"Ophthalmology"},{"key":"1224_CR3","doi-asserted-by":"crossref","unstructured":"Tsai T, Reinehr S, Deppe L, Strubbe A, Kluge N, Dick HB, Joachim SC. Glaucoma Animal Models beyond Chronic IOP Increase. Int J Mol Sci. 2024 Jan 11;25(2):906.","DOI":"10.3390\/ijms25020906"},{"issue":"4","key":"1224_CR4","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.survophthal.2012.08.010","volume":"58","author":"R Vohra","year":"2013","unstructured":"Vohra R, Tsai JC, Kolko M. The role of inflammation in the pathogenesis of glaucoma. Surv Ophthalmol. 2013;58(4):311\u201320.","journal-title":"Surv Ophthalmol"},{"issue":"4","key":"1224_CR5","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1016\/j.ajo.2013.05.027","volume":"156","author":"D Peters","year":"2013","unstructured":"Peters D, Bengtsson B, Heijl A. Lifetime risk of blindness in open-angle glaucoma. Am J Ophthalmol. 2013;156(4):724\u201330.","journal-title":"Am J Ophthalmol"},{"issue":"3","key":"1224_CR6","doi-asserted-by":"publisher","first-page":"540","DOI":"10.7150\/ijms.90273","volume":"21","author":"CC Chuang","year":"2024","unstructured":"Chuang CC, Wang K, Chang CK, Lee CY, Huang JY, Wu HH, et al. Prescription of glucagon-like peptide 1 agonists and risk of subsequent open-angle glaucoma in individuals with type 2 diabetes mellitus. Int J Med Sci. 2024;21(3):540\u20136.","journal-title":"Int J Med Sci"},{"issue":"2","key":"1224_CR7","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1136\/bjophthalmol-2021-319232","volume":"107","author":"J Sterling","year":"2023","unstructured":"Sterling J, Hua P, Dunaief JL, Cui QN, VanderBeek BL. Glucagon-like peptide 1 receptor agonist use is associated with reduced risk for glaucoma. Br J Ophthalmol. 2023;107(2):215\u201320.","journal-title":"Br J Ophthalmol"},{"issue":"9","key":"1224_CR8","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1016\/j.ophtha.2024.03.004","volume":"131","author":"S Niazi","year":"2024","unstructured":"Niazi S, Gnesin F, Thein AS, Andreasen JR, Horwitz A, Mouhammad ZA, et al. Association between Glucagon-like Peptide-1 receptor agonists and the risk of Glaucoma in individuals with type 2 diabetes. Ophthalmology. 2024;131(9):1056\u201363.","journal-title":"Ophthalmology"},{"issue":"5","key":"1224_CR9","doi-asserted-by":"publisher","first-page":"108271","DOI":"10.1016\/j.celrep.2020.108271","volume":"33","author":"JK Sterling","year":"2020","unstructured":"Sterling JK, Adetunji MO, Guttha S, Bargoud AR, Uyhazi KE, Ross AG, et al. GLP-1 receptor agonist NLY01 reduces retinal inflammation and neuron death secondary to ocular hypertension. Cell Rep. 2020;33(5):108271.","journal-title":"Cell Rep"},{"key":"1224_CR10","doi-asserted-by":"publisher","first-page":"1156829","DOI":"10.3389\/fncel.2023.1156829","volume":"17","author":"ECN Lawrence","year":"2023","unstructured":"Lawrence ECN, Guo M, Schwartz TD, Wu J, Lu J, Nikonov S, et al. Topical and systemic GLP-1R agonist administration both rescue retinal ganglion cells in hypertensive glaucoma. Front Cell Neurosci. 2023;17:1156829.","journal-title":"Front Cell Neurosci"},{"key":"1224_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.peptides.2017.04.008","volume":"92","author":"X Ma","year":"2017","unstructured":"Ma X, Lin W, Lin Z, Hao M, Gao X, Zhang Y, et al. Liraglutide alleviates H(2)O(2)-induced retinal ganglion cells injury by inhibiting autophagy through mitochondrial pathways. Peptides. 2017;92:1\u20138.","journal-title":"Peptides"},{"key":"1224_CR12","doi-asserted-by":"publisher","first-page":"589114","DOI":"10.3389\/fphar.2020.589114","volume":"11","author":"HR Zhou","year":"2020","unstructured":"Zhou HR, Ma XF, Lin WJ, Hao M, Yu XY, Li HX, et al. Neuroprotective role of GLP-1 analog for retinal ganglion cells via PINK1\/Parkin-Mediated mitophagy in diabetic retinopathy. Front Pharmacol. 2020;11:589114.","journal-title":"Front Pharmacol"},{"key":"1224_CR13","doi-asserted-by":"publisher","first-page":"1861940","DOI":"10.1155\/2022\/1861940","volume":"2022","author":"L Wei","year":"2022","unstructured":"Wei L, Mo W, Lan S, Yang H, Huang Z, Liang X, et al. GLP-1 RA improves diabetic retinopathy by protecting the Blood-Retinal barrier through GLP-1R-ROCK-p-MLC signaling pathway. J Diabetes Res. 2022;2022:1861940.","journal-title":"J Diabetes Res"},{"key":"1224_CR14","doi-asserted-by":"crossref","unstructured":"Simo R, Bogdanov P, Ramos H, Huerta J, Simo-Servat O, Hernand ez C. Effects of the topical administration of semaglutide on retinal neuroinflammation and vascular leakage in experimental diabetes. Biomedicines. 2021;9(8):926.","DOI":"10.3390\/biomedicines9080926"},{"issue":"15","key":"1224_CR15","doi-asserted-by":"publisher","first-page":"3389","DOI":"10.1111\/bph.15059","volume":"177","author":"R Zhai","year":"2020","unstructured":"Zhai R, Xu H, Hu F, Wu J, Kong X, Sun X. Exendin-4, a GLP-1 receptor agonist regulates retinal capillary tone and restores microvascular patency after ischaemia-reperfusion injury. Br J Pharmacol. 2020;177(15):3389\u2013402.","journal-title":"Br J Pharmacol"},{"key":"1224_CR16","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/1471-2202-13-33","volume":"13","author":"K Hunter","year":"2012","unstructured":"Hunter K, Holscher C. Drugs developed to treat diabetes, liraglutide and lixisenatide, cross the blood brain barrier and enhance neurogenesis. BMC Neurosci. 2012;13:33.","journal-title":"BMC Neurosci"},{"key":"1224_CR17","doi-asserted-by":"crossref","unstructured":"Gabery S, Salinas CG, Paulsen SJ, Ahnfelt-Ronne J, Alanentalo T, Baquero AF et al. Semaglutide lowers body weight in rodents via distributed neural pathways. JCI Insight. 2020;5(6):e133429.","DOI":"10.1172\/jci.insight.133429"},{"key":"1224_CR18","doi-asserted-by":"publisher","first-page":"2583","DOI":"10.2147\/DMSO.S375559","volume":"15","author":"M Dong","year":"2022","unstructured":"Dong M, Wen S, Zhou L. The relationship between the Blood-Brain-Barrier and the central effects of Glucagon-Like Peptide-1 receptor agonists and Sodium-Glucose Cotransporter-2 inhibitors. Diabetes Metab Syndr Obes. 2022;15:2583\u201397.","journal-title":"Diabetes Metab Syndr Obes"},{"issue":"1","key":"1224_CR19","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1167\/tvst.10.1.21","volume":"10","author":"JR Tribble","year":"2021","unstructured":"Tribble JR, Otmani A, Kokkali E, Lardner E, Morgan JE, Williams PA. Retinal ganglion cell degeneration in a rat magnetic bead model of ocular hypertensive Glaucoma. Transl Vis Sci Technol. 2021;10(1):21.","journal-title":"Transl Vis Sci Technol"},{"issue":"1","key":"1224_CR20","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1167\/tvst.10.1.22","volume":"10","author":"JR Tribble","year":"2021","unstructured":"Tribble JR, Kokkali E, Otmani A, Plastino F, Lardner E, Vohra R, et al. When is a control not a control? Reactive microglia occur throughout the control contralateral pathway of retinal ganglion cell projections in experimental Glaucoma. Transl Vis Sci Technol. 2021;10(1):22.","journal-title":"Transl Vis Sci Technol"},{"key":"1224_CR21","doi-asserted-by":"crossref","unstructured":"Hallaj S, Halfpenny W, Chuter BG, Weinreb RN, Baxter SL, Cui QN. Association between Glucagon-Like Peptide 1 (GLP-1) Receptor Agonists Exposure and Intraocular Pressure Change. medRxiv. 2024.","DOI":"10.1101\/2024.05.06.24306943"}],"container-title":["Molecular Brain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13041-025-01224-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13041-025-01224-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13041-025-01224-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T09:15:08Z","timestamp":1751361308000},"score":1,"resource":{"primary":{"URL":"https:\/\/molecularbrain.biomedcentral.com\/articles\/10.1186\/s13041-025-01224-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,1]]},"references-count":21,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1224"],"URL":"https:\/\/doi.org\/10.1186\/s13041-025-01224-8","relation":{},"ISSN":["1756-6606"],"issn-type":[{"value":"1756-6606","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,1]]},"assertion":[{"value":"3 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All experimental procedures were carried out in accordance with the ARVO Statement for the Use of Animals in Ophthalmic and Vision Research. The study protocols were approved by Stockholm\u2019s Committee for Ethical Animal Research (3909\u20132023).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publication"}}],"article-number":"54"}}